Malathion gel - Taro Pharmaceuticals

Drug Profile

Malathion gel - Taro Pharmaceuticals

Alternative Names: MALG

Latest Information Update: 21 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taro Pharmaceuticals USA
  • Class Antiparasitics; Organothiophosphorus compounds; Small molecules
  • Mechanism of Action Cholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pediculosis

Most Recent Events

  • 06 Aug 2012 Phase-III development is ongoing in USA
  • 22 Sep 2011 Taro Pharmaceuticals completes a phase III trial in Pediculosis in the US (NCT00927472)
  • 06 Jun 2011 Taro Pharmaceuticals completes enrolment in its phase II/III trial in Pediculosis (in children 6-24 months) in the US (NCT00752973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top